The current role of secondary cytoreductive surgery for recurrent ovarian cancer

被引:8
作者
de Bree, Eelco [1 ]
Michelakis, Dimosthenis [1 ]
Anagnostopoulou, Elisavet [1 ]
机构
[1] Crete Univ Hosp, Dept Surg Oncol, Med Sch, Iraklion, Greece
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
ovarian cancer recurrence; secondary cytoreductive surgery; patient selection; platinum-sensitive; predictive tools; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; PERITONEAL SURFACE MALIGNANCIES; LEARNING-CURVE; PROGRESSION-FREE; PREDICTION MODELS; AGO SCORE; SURVIVAL; BEVACIZUMAB; MAINTENANCE; MULTICENTER;
D O I
10.3389/fonc.2022.1029976
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer represents worldwide the second most frequent and the most fatal gynecological malignancy, with approximately two thirds of the patients presenting with advanced disease. Cytoreductive surgery, primary or after neoadjuvant chemotherapy, in combination with platinum-based chemotherapy is the standard of care for these patients. Despite the improvement in quality of cytoreductive surgery as well as development of novel drugs and chemotherapy regimens, still most women with ovarian cancer will ultimately develop recurrent disease and die of their disease. In contrast to the management of primary disease, the standard treatment of patients with recurrent ovarian cancer remains a topic of debate. While platinum-based or second line systemic chemotherapy, depending on the time after last platinum treatment, is standard of care, the role of secondary cytoreductive surgery has been a controversial issue for the last decades. Potential outcome benefit must be also weighed against the risk of severe surgical morbidity, impairment of quality of life and costs. In platinum-resistant recurrent disease, i.e., relapse after less than 6 months from the last platinum-based chemotherapy for primary disease, secondary cytoreduction seems generally not to be indicated due to its aggressive biological behavior and the absence of effective systemic treatment. In this comprehensive review, the current role of cytoreductive surgery in platinum-sensitive recurrent ovarian cancer is discussed thoroughly in view of the results of most recent randomized trials and a meta-analysis. There seems to be definitely a role for secondary cytoreductive surgery in selected patients with ovarian cancer recurrence in whom complete resection of macroscopic disease is feasible. However, its role should be continuously reviewed due to the changing systemic treatment of patients with ovarian cancer recurrence over time.
引用
收藏
页数:12
相关论文
共 89 条
[11]   When should Surgery be used for Recurrent Ovarian Carcinoma? [J].
Bommert, M. ;
Harter, P. ;
Heitz, F. ;
du Bois, A. .
CLINICAL ONCOLOGY, 2018, 30 (08) :493-497
[12]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[13]   Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis [J].
Bristow, Robert E. ;
Puri, Isha ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2009, 112 (01) :265-274
[14]   Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [J].
Broglio, Kristine R. ;
Berry, Donald A. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23) :1642-1649
[15]   Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].
Burger, Robert A. ;
Brady, Mark F. ;
Bookman, Michael A. ;
Fleming, Gini F. ;
Monk, Bradley J. ;
Huang, Helen ;
Mannel, Robert S. ;
Homesley, Howard D. ;
Fowler, Jeffrey ;
Greer, Benjamin E. ;
Boente, Matthew ;
Birrer, Michael J. ;
Liang, Sharon X. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483
[16]   Mentored experience of establishing a national peritoneal malignancy programme - Experience of first 50 operative cases [J].
Chang, K. H. ;
Kazanowski, M. ;
Staunton, O. ;
Cahill, R. A. ;
Moran, B. J. ;
Shields, C. ;
Mulsow, J. .
EJSO, 2017, 43 (02) :395-400
[17]   Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis [J].
Chang, Suk-Joon ;
Hodeib, Melissa ;
Chang, Jenny ;
Bristow, Robert E. .
GYNECOLOGIC ONCOLOGY, 2013, 130 (03) :493-498
[18]   Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm [J].
Chi, Dennis S. ;
Eisenhauer, Eric L. ;
Zivanovic, Oliver ;
Sonoda, Yukio ;
Abu-Rustum, Nadeem R. ;
Levine, Douglas A. ;
Guile, Matthew W. ;
Bristow, Robert E. ;
Aghajanian, Carol ;
Barakat, Richard R. .
GYNECOLOGIC ONCOLOGY, 2009, 114 (01) :26-31
[19]   Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma [J].
Chi, DS ;
McCaughty, K ;
Diaz, JP ;
Huh, J ;
Schwabenbauer, S ;
Hummer, AJ ;
Venkatraman, ES ;
Aghajanian, C ;
Sonoda, Y ;
Abu-Rustum, NR ;
Barakat, RR .
CANCER, 2006, 106 (09) :1933-1939
[20]   Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer [J].
Coleman, R. L. ;
Fleming, G. F. ;
Brady, M. F. ;
Swisher, E. M. ;
Steffensen, K. D. ;
Friedlander, M. ;
Okamoto, A. ;
Moore, K. N. ;
Ben-Baruch, N. Efrat ;
Werner, T. L. ;
Cloven, N. G. ;
Oaknin, A. ;
DiSilvestro, P. A. ;
Morgan, M. A. ;
Nam, J. -H. ;
Leath, C. A., III ;
Nicum, S. ;
Hagemann, A. R. ;
Littell, R. D. ;
Cella, D. ;
Baron-Hay, S. ;
Garcia-Donas, J. ;
Mizuno, M. ;
Bell-McGuinn, K. ;
Sullivan, D. M. ;
Bach, B. A. ;
Bhattacharya, S. ;
Ratajczak, C. K. ;
Ansell, P. J. ;
Dinh, M. H. ;
Aghajanian, C. ;
Bookman, M. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2403-2415